Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Glutamate Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Glutamate is an amino acid and a key neurotransmitter in the central nervous system. It acts as an excitatory neurotransmitter, involved in signaling between nerve cells. Glutamate functions by binding to specific receptors, such as NMDA receptors and AMPA receptors, and mediating synaptic transmission and neuronal communication. Glutamate has diverse roles in various physiological processes, including learning, memory, and synaptic plasticity. In terms of disease indications, glutamate dysregulation has been implicated in neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and stroke. Modulating glutamate levels and its receptors are important therapeutic targets in the management of these conditions. According to the World Health Organization (WHO), Alzheimer's disease is a major global health challenge, affecting an estimated 50 million people worldwide, with Europe and the United States having high prevalence rates. In Europe, the number of people with Alzheimer's disease is projected to double by 2050. Parkinson's disease affects approximately 1% of the European population aged 60 years and above, and in the United States, around 1 million individuals are living with the disease. Epilepsy is also a prevalent neurological disorder, with over 6 million people in Europe and 3.4 million people in the United States affected by the condition. Stroke, a leading cause of disability and death globally, affects millions of individuals each year.
The growth drivers of the glutamate market include the increasing prevalence of neurological disorders, advancements in diagnostic techniques, and the development of novel drugs targeting glutamate pathways. Companies such as Biohaven, Galderma, AbbVie, Medytox, MeiraGTx, AstraZeneca, Aptinyx, Eirion, Addex, Huons, Synchroneuron, Eli Lilly, MetVital, Ipsen, ATGC Co, Hugel, Novartis, CleveXel Pharma, Daiichi Sankyo, Sage Therapeutics, Camino Pharma, Italfarmaco, Chong Kun Dang, Intra-Cellular Therapies, Saniona, Tonix cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, AstraZeneca is one such company that is currently conducting a clinical trial of the drug Omipalisib AZD2516 for the treatment of idiopathic pulmonary fibrosis.
Glutamate Market Key Developments:
Approved Glutamate Molecules
Glutamate Pipeline Molecules
Clinical Activity and Development of Glutamate
In the Glutamate space, more than 15 companies are conducting around 150 clinical trials in this category of drugs. For instance,
Product Name |
Total Studies |
Troriluzole (BHV-4157) |
12 |
Botulinum toxin E (AGN-151586) |
7 |
relabotulinumtoxina (QM1114) |
7 |
Botulinum toxin A (MBA-P01) |
6 |
AZD2516 |
5 |
NYX-2925 |
5 |
Botulinum toxin A topical (ET-01) |
5 |
Raseglurant (ADX-10059) |
5 |
NYX-783 |
3 |
Acamprosate controlled-release (SNC-102) |
3 |
KLS-2031 |
2 |
LY545694 |
2 |
Botulinum toxin A longer acting (IPN10200) |
2 |
Botulinum toxin type A (ATGC-110) |
2 |
Botulinum toxin type A (HG-102) |
2 |
Clostridium botulinum neurotoxin serotype A recombinant (IPN59011) |
2 |
CAD-9303 |
1 |
CVXL-0107 |
1 |
DS-1150b |
1 |
NYX-458 |
1 |
Glutamate is targeted as a potential therapeutic intervention for various indications related to neurological disorders. It plays a crucial role in the pathophysiology of conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, and stroke. In Alzheimer's disease, the dysregulation of glutamate receptors and excitotoxicity contribute to neuronal damage and cognitive decline. In Parkinson's disease, disrupted glutamate signaling is implicated in motor symptoms and neurodegeneration. Epilepsy involves abnormal glutamate release and receptor activation leading to seizures. Stroke is associated with excessive glutamate release, leading to neuronal excitotoxicity and ischemic damage. Targeting glutamate pathways aims to modulate its levels and receptor activity, potentially offering therapeutic benefits in managing these neurological disorders.
Download Free Sample Report
Glutamate drugs are used in the management of Alzheimer's disease, Parkinson's disease, epilepsy, and stroke.
The growth drivers of the glutamate market include the increasing prevalence of neurological disorders, advancements in diagnostic techniques, and the development of novel drugs targeting glutamate pathways.
The major players in this space are Biohaven, Galderma, AbbVie, Medytox, MeiraGTx, AstraZeneca, Aptinyx, Eirion, Addex, Huons, Synchroneuron, Eli Lilly, MetVital, Ipsen, ATGC Co, Hugel, Novartis, CleveXel Pharma, Daiichi Sankyo, Sage Therapeutics, Camino Pharma, Italfarmaco, Chong Kun Dang, Intra-Cellular Therapies, Saniona, Tonix.
The market for glutamate faces restraints due to challenges associated with targeting and modulating glutamate pathways effectively without disrupting normal physiological functions. Additionally, the complexity of glutamate signaling and its involvement in multiple disease indications pose difficulties in developing specific and selective therapeutic interventions, limiting the growth and adoption of glutamate-targeted treatment.
Key Market Players